Short Interest in Lipocine Inc. (NASDAQ:LPCN) Increases By 155.6%

Lipocine Inc. (NASDAQ:LPCN) was the recipient of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 278,400 shares, an increase of 155.6% from the March 31st total of 108,900 shares. Approximately 5.4% of the company’s stock are sold short. Based on an average trading volume of 61,900 shares, the days-to-cover ratio is presently 4.5 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on Lipocine in a report on Friday, April 19th. They issued a “sell” rating for the company.

Lipocine Price Performance

NASDAQ LPCN traded up $0.26 on Friday, reaching $4.81. The company had a trading volume of 19,754 shares, compared to its average volume of 60,050. The firm has a market capitalization of $25.73 million, a PE ratio of -1.58 and a beta of 1.05. Lipocine has a 1 year low of $2.31 and a 1 year high of $7.15. The firm has a 50-day moving average of $4.58 and a 200-day moving average of $3.56.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.11. The business had revenue of $0.22 million during the quarter. As a group, sell-side analysts expect that Lipocine will post -1.49 EPS for the current fiscal year.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.